secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-08-03T20:09:02+00:00
Accession:  0001658247-26-000052
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex to acquire Crinetics for $85/share (~$10B equity value); Q2 PALSONIFY revenue $24M
--------------------------------------------------------------------------------

- Vertex to acquire Crinetics for $85.00 per share cash, total equity value ~$10.0B (~$8.8B net of cash).
- Transaction approved by both boards, expected to close Q3 2026 subject to regulatory and stockholder approvals.
- Q2 2026 net product revenue from PALSONIFY $24.0M, up from $10.3M in Q1 2026.
- Net loss $120.9M for Q2 2026 vs $115.6M in Q2 2025.
- Cash and investments $1.2B as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/0001658247-26-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/crnx-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001658247-26-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer